Astrazeneca (AZN) Non-Current Deffered Revenue (2018 - 2023)

Astrazeneca (AZN) has reported Non-Current Deffered Revenue for 6 consecutive years, with $7.0 million the latest figure, recorded in Q4 2023.

• In Q4 2023, Non-Current Deffered Revenue fell 50.0% year-over-year to $7.0 million; the TTM figure through Dec 2023 stood at $7.0 million (down 50.0% YoY), while the FY2023 annual figure was $7.0 million, down 50.0% from the prior year.
• Non-Current Deffered Revenue came in at $7.0 million for Q4 2023 at Astrazeneca, down from $14.0 million in the prior quarter.
• The five-year high for Non-Current Deffered Revenue was $50.0 million in Q4 2019, with the low at $7.0 million in Q4 2023.
• Average Non-Current Deffered Revenue over 5 years is $27.0 million, with a median of $26.0 million recorded in 2021.
• Across the five-year window, Non-Current Deffered Revenue dropped 24.0% in 2020 and slumped 50.0% in 2023, its largest moves.
• Year by year, Non-Current Deffered Revenue stood at $50.0 million in 2019, then decreased by 24.0% to $38.0 million in 2020, then plunged by 31.58% to $26.0 million in 2021, then slumped by 46.15% to $14.0 million in 2022, then plunged by 50.0% to $7.0 million in 2023.
• According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $7.0 million, $14.0 million, and $26.0 million for Q4 2023, Q4 2022, and Q4 2021 respectively.